Orion OyjORINF +4.81%100 ROE % is 29.84% as of Mar. 2026, which is 14% below its 10-year median of 34.52. GuruFocus rates ORINF with a GF Score™ of 100/100 and a GF Value™ of $86.78. The stock has 2 warning signs investors should review. Among 936 Drug Manufacturers companies, Orion Oyj ranks better than 96.47% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Orion Oyj's annualized net income for the quarter that ended in Mar. 2026 was $418 Mil. Orion Oyj's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $1,401 Mil. Therefore, Orion Oyj's annualized ROE % for the quarter that ended in Mar. 2026 was 29.84%.
The historical rank and industry rank for Orion Oyj's ROE % or its related term are showing as below:
ORINF'
s ROE % Range Over the Past 10 Years
Min: 24.11 Med: 34.52 Max: 48.91
Current: 48.91
During the past 13 years, Orion Oyj's highest ROE % was 48.91%. The lowest was 24.11%. And the median was 34.52%.
ORINF's ROE % is ranked better than 96.47% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs ORINF: 48.91
Orion Oyj (OTCPK:ORINF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Orion Oyj ROE % Related Terms
Orion Oyj ROE % Historical Data
* Premium members only.
The historical data trend for Orion Oyj's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Orion Oyj's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's ROE % distribution charts can be found below:
* The bar in red indicates where Orion Oyj's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Orion Oyj (ORINF) has a ROE % of 29.84% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Orion Oyj and its competitors. This is 14% below median its historical median of 34.52. Over the past decade, Orion Oyj's ROE % has ranged from 24.11 to 48.91. According to the industry distribution chart, Orion Oyj ranks #33 out of 936 companies in the Drug Manufacturers industry, placing it in the top 3.5%.
Is Orion Oyj's ROE % too high?
Orion Oyj's current ROE % of 29.84% is 14% below median its 10-year median of 34.52. Over the past 10 years, this metric has ranged from a low of 24.11 to a high of 48.91. The Drug Manufacturers industry median ROE % is 5.87. Orion Oyj's value of 29.84% is 408.8% above this industry median. Based on the distribution chart, Orion Oyj ranks #33 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orion Oyj has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's ROE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #33 out of 936 companies for ROE %. This places Orion Oyj in the top 4% of its industry — outperforming the majority of peers. The industry median ROE % is 5.87. Orion Oyj's value of 29.84% is 408.8% above this benchmark. Historically, Orion Oyj's own ROE % has ranged from 24.11 to 48.91 over the past decade. While the company's 10-year median is 34.52 vs. the industry median of 5.87, Orion Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current ROE % of 29.84% is 408.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Orion Oyj and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current ROE % is 29.84%, which is 14% below median its own 10-year median of 34.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Orion Oyj (ORINF) has a current ROE % of 29.84%. The stock's GF Value™ is $86.78, compared to a current price of $82.75 — trading 4.6% below its estimated fair value. The current ROE % is 29.84%, which is 14% below median its 10-year median of 34.52 and 408.8% above the Drug Manufacturers industry median of 5.87. Orion Oyj's overall GF Score™ is 100/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Orion Oyj (ORINF), the current ROE % is 29.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (ORINF) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be undervalued.
The current stock price of $82.75 is trading 4.6% below its estimated GF Value™ of $86.78.
Key valuation signals for ORINF:
ROE %: 29.84% (14% below median its 10-year median of 34.52)
GF Value™: $86.78 vs. price of $82.75 (4.6% below fair value)
Industry Position: 408.8% above the Drug Manufacturers median (#33 of 936)
No single metric tells the full story. See the ORINF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
100GF Score
Get the complete analysis for ORINF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORINF has been successfully added to your 
